PrecisemAb Biotech Co,.Ltd
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
Our Universal Antibody Lock™ technology is an innovative, proprietary platform designed to generate conditionally-activated antibody therapeutics for a variety of antibody formats, including monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. This technology not only enhances antibody selectivity but also reduces on-target toxicity, delivering safer and more effective therapeutic solutions for patients.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2020
Unified Business No.
83392679
Status
Closed
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Kaohsiung City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Now renamed as Shuo Zhun Biotechnology Co., Ltd., PrecisemAb was jointly established by a team led by Chair Professor Tian-Lu Cheng, Dr. Yun-Chi Lu, and Dr. Yi-An Cheng of Kaohsiung Medical University. Having deeply cultivated the field of antibody engineering for 25 years, Professor Tian-Lu Cheng successfully developed the globally unique "Antibody Lock" technology, which can effectively enhance the selectivity of antibody drugs toward disease areas and reduce drug side effects, bringing a revolutionary breakthrough to the safety of antibody drugs. Upholding the spirit of "contributing to society with professionalism," Professor Tian-Lu Cheng will lead the team to continuously create a more reassuring treatment environment for patients.
(The content above was translated by AI.)
(The content above was translated by AI.)
